Vanda Q3 revenue up 18% to $56.3M but net loss widens to $22.6M; guidance lowered

Vanda Pharmaceuticals Inc.

2025-Q3 EPS reported -$1.35 revenue$158,889,000

Total net product sales $56.3M (+18% YoY): Fanapt $31.2M (+31%), HETLIOZ $18.0M (+1%), PONVORY $7.0M (+20%).
Net loss $22.6M (diluted EPS -$0.38) vs loss $5.3M (-$0.09) in Q3 2024.
FY2025 guidance: revenue $210-$230M (prev. $210-$250M); year-end cash $260-$290M (prev. $280-$320M).
Pipeline: Tradipitant NDA PDUFA Dec 30, 2025; Bysanti NDA Feb 21, 2026; Imsidolimab BLA filing expected Q4 2025.
Cash $293.8M at Sep 30, 2025, down $80.9M from Dec 31, 2024 and $31.8M from Jun 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.